证券代码：301075 证券简称：多瑞医药 公告编号：2025-058 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理的 议案》，同意公司使用最高不超过人民币 32,000 万元（含本数）的闲 置募集资金进行现金管理，用于购买安全性高、流动性好、不影响公 司正常经营的理财产品。使用期限为自公司董事会审议通过之日起12 个月内，在上述使用期限及额度范围内，资金可循环滚动使用。在额 度范围内授权公司法定代表人及其授权人士签署相关合同文件，授权 期限自董事会审议通过之日起 12 个月内有效。该事项已经公司董事 会、监事会审议通过，保荐机构中信证券股份有限公司对公司使用部 分暂时闲置募集资金进行现金管理出具了明确的核查意见。具体内容 详见于巨潮资讯网（www.cninfo.com.cn）《关于使 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-057 西藏多瑞医药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 二、控股股东及其一致行动人股份质押情况 截至公告披露日，控股股东及其一致行动人累计质押股份数占其 持股总数的比例为 49.24%。质押股份整体风险可控，目前不存在平 仓风险或被强制过户风险，不存在股份被冻结、被拍卖或设定信托的 情形；公司控股股东及其一致行动人不存在非经营性资金占用、违规 担保等侵害上市公司利益的情形；本次股份质押事项对公司生产经营、 公司治理等不产生实质性影响。 公司将持续关注其股份质押变动情况及风险，并及时履行信息披 露义务。敬请广大投资者注意风险。 三、备查文件 西藏多瑞医药股份有限公司（以下简称"公司"）近日收到公司控 股股东西藏嘉康时代科技发展有限公司（以下简称"西藏嘉康"）通知， 获悉西藏嘉康所持有本公司的部分股权被质押，具体事项公告如下： 一、股份质押的基本情况 （二）股东股份累计被质押的情况 股东 姓名 是否为第一 大股东及其 一致行动人 本次质押 数量 （股） 占其所 持股份 比例 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

Core Viewpoint - Duorui Pharmaceutical (301075) has received approval from the National Medical Products Administration for the injection of Cefoperazone Sodium, indicating a significant development in its product portfolio [1] Company Summary - Duorui Pharmaceutical's wholly-owned subsidiary, Hubei Duorui Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Cefoperazone Sodium injection, with specifications of 0.5g/1.0g [1] - The drug registration certificate is valid until June 9, 2030, with certificate numbers 2025S01726/2025S01727 and approval numbers H20254471/H20254472 [1] Industry Summary - Sales data from 2022 to 2024 for Cefoperazone Sodium injection shows revenue figures of 4.139 billion, 4.144 billion, and 3.078 billion respectively, indicating a slight decline in projected sales for 2024 [1]

二、药品其他情况 证券代码：301075 证券简称：多瑞医药 公告编号：2025-056 西藏多瑞医药股份有限公司 关于全资子公司获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）全资子公司湖北 多瑞药业有限公司近日收到国家药品监督管理局核准签发的关于注 射用头孢唑肟钠的《药品注册证书》，现将有关信息公告如下： 药品名称 注射用头孢唑肟钠 主要成分 头孢唑肟钠 剂型 注射剂 规格 0.5g/1.0g 证书编号 2025S01726/2025S01727 药品批准文号 国药准字 H20254471/国药准字 H20254472 药品批准文号有 效期 至 2030 年 06 月 09 日 申请事项 药品注册（境内生产） 注册分类 化学药品 4 类 处方药/非处方药 处方药 上市许可持有人 名称：湖北多瑞药业有限公司 地址：湖北省荆州市公安县斗湖堤镇孱陵大道 生产企业 名称：深圳立健药业有限公司 地址：深圳市龙华区大浪街道上横朗社区园富路 1 号 一、药品基本情况 | | 根据《中华人民共和国药品管理 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-055 | 序 | 购买 | 受托方名称 | 产品名称 | 金额 | 产品 | 产品起息 | 产品 | 预期年化 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 主体 | | | （万元） | 类型 | 日 | 到期日 | 收益率 | | 1 | 湖北多瑞药 | 恒丰银行股份有限 | 恒丰银行可转让 | 3,000 | 保本大 | 2025/6/11 | 2025/9/11 | 1.1000% | | | 业有限公司 | 公司武汉分行 | 单位大额存单 | | 额存单 | | | | 注：上述金额未扣除交易费用，下同。 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现金 管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《 ...

Core Insights - The latest financing balance of the ChiNext market is 340.12 billion yuan, with a week-on-week increase of 1.03 billion yuan, indicating a positive trend in market financing activity [1][2] Financing Balance Overview - The total margin balance for ChiNext stocks reached 341.06 billion yuan, an increase of 1.04 billion yuan from the previous trading day, with the financing balance at 340.12 billion yuan, up by 1.03 billion yuan [1] - The margin balance for short selling was 93.7 million yuan, reflecting a week-on-week increase of 13.95 million yuan [1] Stocks with Increased Financing Balance - A total of 500 ChiNext stocks saw an increase in financing balance, with 36 stocks experiencing a growth rate exceeding 10% [1] - The stock with the highest increase in financing balance is Aoya Co., Ltd., with a latest financing balance of 65.55 million yuan, showing a week-on-week increase of 33.67% and a price increase of 20.00% on the same day [1][3] - Other notable stocks with significant financing balance increases include Fosa Technology and Hopson Co., Ltd., with increases of 28.81% and 26.58%, respectively [1][3] Market Performance of Stocks - Among the stocks with a financing balance increase of over 10%, the average price increase on the same day was 3.89%, with 26 stocks rising and two stocks, Aoya Co., Ltd. and Lepu Medical, hitting the daily limit [1] - Stocks with the largest price increases included Mankalon, Tianyuan Pet, and Xingyun Co., Ltd., with increases of 17.01%, 16.81%, and 15.34%, respectively [1] Stocks with Decreased Financing Balance - A total of 432 stocks experienced a decrease in financing balance, with 41 stocks showing a decline of over 5% [4] - The stock with the largest decrease in financing balance is Green Island Wind, with a latest financing balance of 22.39 million yuan, reflecting a decrease of 26.68% [4][5] - Other stocks with significant declines include Superjet Co., Ltd. and Kaile Co., Ltd., with decreases of 13.94% and 13.00%, respectively [4][5] Capital Flow Analysis - On June 4, among the stocks with increased financing balances, 29 stocks saw net inflows of main funds, with Lepu Medical, Kidswant, and Tianyuan Pet leading with net inflows of 391 million yuan, 70.54 million yuan, and 66.33 million yuan, respectively [2] - Conversely, seven stocks experienced net outflows, with Mankalon, Hopson Co., Ltd., and Langxin Group seeing the largest outflows of 58.55 million yuan, 31.15 million yuan, and 27.89 million yuan, respectively [2]

化学制药板块短线走低，华纳药厂跌超9%，天宇股份（300702）、舒泰神（300204）、多瑞医药 （301075）、海创药业等跟跌。 ...

关于使用暂时闲置募集资金进行现金管理的进展公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 证券代码：301075 证券简称：多瑞医药 公告编号：2025-054 西藏多瑞医药股份有限公司 注：上述金额未扣除交易费用，下同。 二、 关联关系说明 公司与上述委托理财的受托方不存在关联关系，公司本次进行现 金管理不涉及关联交易。 三、 投资风险分析及风险控制措施 公司进行现金管理购买的产品属于安全性高的投资品种，但不排 除该项投资受到市场波动的影响。针对可能发生的收益风险，公司制 定如下措施： 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理的 议案》，同意公司使用最高不超过人民币 32,000 万元（含本数）的闲 置募集资金进行现金管理，用于购买安全性高、流动性好、不影响公 司正常经营的理财产品。使用期限为自公司董事会审议通过之日起12 个月内，在上述使用期限及额度范围内，资金可循环 ...

Core Viewpoint - The latest financing balance of the ChiNext market is 339.346 billion yuan, with a week-on-week increase of 0.383 billion yuan, indicating a mixed performance among individual stocks in terms of financing balance changes [1][2]. Financing Balance Overview - As of May 26, the total margin balance of ChiNext stocks reached 340.278 billion yuan, an increase of 0.347 billion yuan from the previous trading day, with a financing balance of 339.346 billion yuan and a securities lending balance of 93.2 million yuan [1]. - A total of 447 stocks saw an increase in financing balance, with 26 stocks experiencing a growth of over 10% [1][3]. Notable Stocks with Increased Financing Balance - The stock with the highest increase in financing balance is Honggong Technology, which saw a financing balance of 63.481 million yuan, reflecting a week-on-week increase of 57.83% and a price increase of 2.51% [1][3]. - Other notable stocks with significant increases include Duorui Pharmaceutical and Demais, with increases of 47.30% and 39.00%, respectively [1][3]. Market Performance of Stocks with Increased Financing - Among the stocks with a financing balance increase of over 10%, the average price increase on that day was 0.88%, with 15 stocks rising [1][2]. - The top gainers included Xinbang Intelligent, Biaobang Co., and Chongde Technology, with increases of 16.16%, 8.95%, and 7.29%, respectively [1][2]. Stocks with Decreased Financing Balance - A total of 485 stocks experienced a decrease in financing balance, with 42 stocks showing a decline of over 5% [4]. - The stock with the largest decrease was Fusa Technology, with a financing balance of 47.5304 million yuan, reflecting a decline of 15.26% [4][5]. Notable Stocks with Decreased Financing Balance - Other significant decliners included Qide New Materials and Qushui Technology, with decreases of 14.99% and 13.09%, respectively [4][5]. - The overall trend indicates a mixed performance in the ChiNext market, with both increases and decreases in financing balances across various sectors [1][4].